Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 10506

Next Previous
X
Search
Drug Profile

HS 10506

Alternative Names: HS-10506

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Antidepressants; Sleep disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders; Insomnia

Most Recent Events

  • 26 Feb 2024 Jiangsu Hansoh Pharmaceutical plans a phase Ib/II trial in Insomnia(In adults) in China (PO, Tablet) in March 2024 (NCT06279286)
  • 12 Jul 2023 Jiangsu Hansoh Pharmaceutical plans a phase I trial (In volunteers) in China (PO) in July 2023 (NCT05953506)
  • 04 May 2023 Preclinical trials in Depressive disorders in China (PO) prior to May 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top